Raj AT, Patil S, Rajkumar C, et al. Assessing the role of immune system in cancer progression from minimal residual disease. Oral Oncol 2017;75:180–181. DOI: 10.1016/j.oraloncology.2017.10.017.
Raj AT, Kheur S. Hypothesizing the potential implications of exposing known carcinogens on normal stem cells. Oral Oncol 2018;79:86–87. DOI: 10.1016/j.oraloncology.2018.02.020.
Raj AT, Kheur S, Bhonde R, et al. Use of bone marrow-derived mesenchymal stem cells in prostate cancer could increase the risk of cancer progression. Stem Cells Transl Med 2019;8(7):737–738. DOI: 10.1002/sctm.19-0050.
Ji X, Zhang Z, Han Y, et al. Mesenchymal stem cells derived from normal gingival tissue inhibit the proliferation of oral cancer cells in vitro and in vivo. Int J Oncol 2016;49(5):2011–2022. DOI: 10.3892/ijo.2016.3715.
Papaccio F, Paino F, Regad T, et al. Concise review: cancer cells, cancer stem cells, and Mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med 2017;6(12):2115–2125. DOI: 10.1002/sctm.17-0138.
Barcellos-de-Souza P, Comito G, Pons-Segura C, et al. Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1. Stem Cells 2016;34(10):2536–2547. DOI: 10.1002/stem.2412.
Schweizer MT, Wang H, Bivalacqua TJ, et al. A phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer. Stem Cells Transl Med 2019;8(5):441–449. DOI: 10.1002/sctm.18-0230.